Boston Scientific Co. (NYSE:BSX) Shares Acquired by Gitterman Wealth Management LLC

Gitterman Wealth Management LLC boosted its position in shares of Boston Scientific Co. (NYSE:BSX) by 4.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,959 shares of the medical equipment provider’s stock after purchasing an additional 168 shares during the period. Gitterman Wealth Management LLC’s holdings in Boston Scientific were worth $354,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. CBIZ Investment Advisory Services LLC grew its holdings in Boston Scientific by 41.3% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 3,080 shares of the medical equipment provider’s stock worth $275,000 after acquiring an additional 900 shares in the last quarter. one8zero8 LLC acquired a new position in Boston Scientific during the 4th quarter worth $250,000. Choate Investment Advisors grew its holdings in Boston Scientific by 20.0% during the 4th quarter. Choate Investment Advisors now owns 4,084 shares of the medical equipment provider’s stock worth $365,000 after acquiring an additional 680 shares in the last quarter. Natixis Advisors LLC grew its holdings in Boston Scientific by 10.0% during the 4th quarter. Natixis Advisors LLC now owns 2,030,069 shares of the medical equipment provider’s stock worth $181,326,000 after acquiring an additional 184,264 shares in the last quarter. Finally, Frank Rimerman Advisors LLC grew its holdings in Boston Scientific by 1.5% during the 4th quarter. Frank Rimerman Advisors LLC now owns 20,571 shares of the medical equipment provider’s stock worth $1,837,000 after acquiring an additional 299 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Boston Scientific

In related news, CFO Daniel J. Brennan sold 67,333 shares of the business’s stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $105.24, for a total transaction of $7,086,124.92. Following the transaction, the chief financial officer now owns 225,808 shares of the company’s stock, valued at approximately $23,764,033.92. The trade was a 22.97 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP John Bradley Sorenson sold 1,201 shares of the business’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $106.31, for a total transaction of $127,678.31. Following the transaction, the executive vice president now directly owns 25,443 shares in the company, valued at $2,704,845.33. This trade represents a 4.51 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 137,302 shares of company stock worth $14,319,269. 0.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Needham & Company LLC reissued a “hold” rating on shares of Boston Scientific in a report on Monday, March 3rd. Stifel Nicolaus raised their price target on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a research report on Thursday, February 6th. Canaccord Genuity Group raised their price target on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Citigroup raised their price target on shares of Boston Scientific from $107.00 to $122.00 and gave the stock a “buy” rating in a research report on Thursday, February 6th. Finally, UBS Group raised their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Two investment analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $108.91.

Boston Scientific Stock Performance

BSX stock opened at $97.26 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The stock has a market cap of $143.53 billion, a P/E ratio of 77.81, a P/E/G ratio of 2.79 and a beta of 0.77. The firm has a 50 day simple moving average of $101.05 and a 200 day simple moving average of $91.76. Boston Scientific Co. has a 52 week low of $66.16 and a 52 week high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Research analysts anticipate that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.